Impact of the COVID-19 Outbreak on the management of patients with gynecological cancers
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
OBJECTIVE: The exceptional health situation related to the SARS-Cov2 coronavirus pandemic (COVID-19) required a deep and very quickly adaptation of management practices in gynecological cancer. The main objective is to estimate the proportion of patients with treatment modifications.
METHOD: This is a multicenter prospective study conducted in 3 university gynecological cancer departments (HCLyon, France) during the period of confinement (March 16 to May 11, 2020). All patients with non-metastatic breast cancer or gynecological cancer were included. The planned treatment, postponement, delay and organizational modifications (RCP, teleconsultations) were studied.
RESULTS: Two hundred and five consecutive patients were included, average age 60.5±1.0. 7 patients (3.4%) had SARS-Cov-2 infection, 2 patients died. One hundred and twenty-two patients (59.5%) had a treatment maintained, 72 patients (35.1%) postponed, 11 patients (5.4%) cancelled. Of the 115 (56.1%) planned surgeries, 40 (34.8%) postponed, 7 cancelled (6.1%). 9 patients (7.8%) had a surgical modification. Of the 59 (28.8%) radiotherapy treatments scheduled, 24 (40.7%) postponed and 2 (3.4%) cancelled. Of the 56 (27.3%) chemotherapy treatment planned, 8 (14.3%) postponed and 2 (3.6%) cancelled. One hundred and forty-five patients (70.7%) have been discussed in multidisciplinary meeting. One hundred and fifty-eight patients (77%) had a teleconsultation system.
CONCLUSION: Our study assessed the impact of the COVID-19 pandemic on therapeutic management of patients with gynecological cancer during the period of confinement. This will probably improve our management of an eventual epidemic rebound or future health crisis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Gynecologie, obstetrique, fertilite & senologie - 48(2020), 11 vom: 15. Nov., Seite 777-783 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Impact de la pandémie de Covid-19 sur les modifications thérapeutiques des patientes atteintes de cancers gynécologiques |
|---|
| Beteiligte Personen: |
Lamblin, G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 19.11.2020 Date Revised 10.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gofs.2020.09.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315807873 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315807873 | ||
| 003 | DE-627 | ||
| 005 | 20231225155720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.gofs.2020.09.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1052.xml |
| 035 | |a (DE-627)NLM315807873 | ||
| 035 | |a (NLM)33010487 | ||
| 035 | |a (PII)S2468-7189(20)30268-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lamblin, G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of the COVID-19 Outbreak on the management of patients with gynecological cancers |
| 246 | 3 | 3 | |a Impact de la pandémie de Covid-19 sur les modifications thérapeutiques des patientes atteintes de cancers gynécologiques |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.11.2020 | ||
| 500 | |a Date Revised 10.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a OBJECTIVE: The exceptional health situation related to the SARS-Cov2 coronavirus pandemic (COVID-19) required a deep and very quickly adaptation of management practices in gynecological cancer. The main objective is to estimate the proportion of patients with treatment modifications | ||
| 520 | |a METHOD: This is a multicenter prospective study conducted in 3 university gynecological cancer departments (HCLyon, France) during the period of confinement (March 16 to May 11, 2020). All patients with non-metastatic breast cancer or gynecological cancer were included. The planned treatment, postponement, delay and organizational modifications (RCP, teleconsultations) were studied | ||
| 520 | |a RESULTS: Two hundred and five consecutive patients were included, average age 60.5±1.0. 7 patients (3.4%) had SARS-Cov-2 infection, 2 patients died. One hundred and twenty-two patients (59.5%) had a treatment maintained, 72 patients (35.1%) postponed, 11 patients (5.4%) cancelled. Of the 115 (56.1%) planned surgeries, 40 (34.8%) postponed, 7 cancelled (6.1%). 9 patients (7.8%) had a surgical modification. Of the 59 (28.8%) radiotherapy treatments scheduled, 24 (40.7%) postponed and 2 (3.4%) cancelled. Of the 56 (27.3%) chemotherapy treatment planned, 8 (14.3%) postponed and 2 (3.6%) cancelled. One hundred and forty-five patients (70.7%) have been discussed in multidisciplinary meeting. One hundred and fifty-eight patients (77%) had a teleconsultation system | ||
| 520 | |a CONCLUSION: Our study assessed the impact of the COVID-19 pandemic on therapeutic management of patients with gynecological cancer during the period of confinement. This will probably improve our management of an eventual epidemic rebound or future health crisis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Cancer du sein | |
| 650 | 4 | |a Cancer gynécologique | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a Covid-19 | |
| 650 | 4 | |a Gynecological cancer | |
| 650 | 4 | |a Pandemic period | |
| 650 | 4 | |a Pandémie | |
| 650 | 4 | |a SARS-Cov-2 | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Golfier, F |e verfasserin |4 aut | |
| 700 | 1 | |a Peron, J |e verfasserin |4 aut | |
| 700 | 1 | |a Moret, S |e verfasserin |4 aut | |
| 700 | 1 | |a Chene, G |e verfasserin |4 aut | |
| 700 | 1 | |a Nohuz, E |e verfasserin |4 aut | |
| 700 | 1 | |a Lebon, M |e verfasserin |4 aut | |
| 700 | 1 | |a Dubernard, G |e verfasserin |4 aut | |
| 700 | 1 | |a Cortet, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gynecologie, obstetrique, fertilite & senologie |d 2017 |g 48(2020), 11 vom: 15. Nov., Seite 777-783 |w (DE-627)NLM269302743 |x 2468-7189 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2020 |g number:11 |g day:15 |g month:11 |g pages:777-783 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gofs.2020.09.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2020 |e 11 |b 15 |c 11 |h 777-783 | ||